Drug Trial Radar · NCT03523728
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Last checked: Nov 19, 2026Latest source record: Feb 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
478
Actual
Start
Oct 4, 2018
Primary completion
Aug 3, 2021
Study completion Aug 3, 2021
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: * To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). * To evaluate the pharmacokinetics (PK) of venglustat in ADPKD participants (Stages 1 and 2). * To determine the effect of venglustat on pain and fatigue, based on participant reported diary (Stages 1 and 2). * Safety/tolerability objectives: * To characterize the safety profile of venglustat (Stages 1 and 2). * To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2). * To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).
Conditions
- Polycystic Kidney, Autosomal Dominant
Interventions
VenglustatDrug
Pharmaceutical form: capsule; Route of administration: oral
PlaceboDrug
Pharmaceutical form: capsule; Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1Time frame: From Baseline to Month 18
- Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2Time frame: From Baseline to Month 24
Locations
95 sites in 23 countries. Site status is shown where the registry gives one.
Investigational Site Number 8400002
Birmingham, Alabama
Investigational Site Number 8400017
Los Angeles, California
Investigational Site Number 8400001
San Francisco, California
Investigational Site Number 8400008
Aurora, Colorado
Investigational Site Number 8400010
New Haven, Connecticut
Investigational Site Number 8400004
Atlanta, Georgia
Investigational Site Number 8400007
Chicago, Illinois
Investigational Site Number 8400014
Iowa City, Iowa
Investigational Site Number 8400003
Kansas City, Kansas
Investigational Site Number 8400021
Baltimore, Maryland
Investigational Site Number 8400016
Boston, Massachusetts
Investigational Site Number 8400020
Rochester, Minnesota
Investigational Site Number 8400027
Kansas City, Missouri
Investigational Site Number 8400011
Philadelphia, Pennsylvania
Investigational Site Number 8400015
San Antonio, Texas
Investigational Site Number 8400019
Morgantown, West Virginia
Investigational Site Number 8400005
Madison, Wisconsin
Investigational Site Number 8400006
Milwaukee, Wisconsin
Investigational Site Number 0320001
Buenos Aires, Argentina
Investigational Site Number 0320003
Santa Fe, Argentina
Investigational Site Number 0360002
Herston, Australia
Investigational Site Number 0360003
Nedlands, Australia
Investigational Site Number 0360001
Westmead, Australia
Investigational Site Number 0400001
Graz, Austria
Investigational Site Number 0400004
Vienna, Austria
Investigational Site Number 0560001
Brussels, Belgium
Investigational Site Number 0560002
Leuven, Belgium
Investigational Site Number 1240002
Edmonton, Canada
Investigational Site Number 1240003
Montreal, Canada
Investigational Site Number 1240001
Toronto, Canada
Investigational Site Number 1560005
Beijing, China
Investigational Site Number 1560004
Chengdu, China
Investigational Site Number 1560009
Guangzhou, China
Investigational Site Number 1560006
Hangzhou, China
Investigational Site Number 1560002
Hefei, China
Investigational Site Number 1560007
Nanjing, China
Investigational Site Number 1560008
Nanjing, China
Investigational Site Number 1560001
Shanghai, China
Investigational Site Number 1560003
Shenyang, China
Investigational Site Number 2030001
Prague, Czechia
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.